Page 23 - அல்லாத சிறிய செல் நுரையீரல் புற்றுநோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NANTES, France, Feb. 23, 2021 (GLOBE NEWSWIRE) OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of the Company’s business at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-11, 2021. The presentation will be available for on-demand listening beginning March 9 at 7:00 am (EST) / 1:00 pm (CET) and archived for 90 days. Webcasting link: ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile:

Alexis peyrolesHc wainwright global life sciences conferenceBoehringer ingelheimChief executive officerGlobal life sciences conferenceNon small cell lung cancerOse immunotherapeutics stock exchangePress releaseAt ose fr0012127173ஹ்ஸீ வேந்‌ரைட் உலகளாவிய வாழ்க்கை அறிவியல் மாநாடுபோஹெரிங்கர் இஂகல்‌ஹைம்தலைமை நிர்வாகி அதிகாரிஉலகளாவிய வாழ்க்கை அறிவியல் மாநாடுஅல்லாத சிறிய செல் நுரையீரல் புற்றுநோய்ப்ரெஸ் வெளியீடு